December 6, 2010 – The U.S. Food and Drug Administration (FDA) has given conditional approval for a trial that will investigate the role of a device in reducing infarct size in patients with ST-elevation myocardial infarction (STEMI). The MINI-AMI trial will use the Impella 2.5, from Abiomed, for 24 hours following primary percutaneous intervention (PCI).

December 6, 2010 - A blood vessel dysfunction that is linked to cardiovascular illness also appears to play a role in the development of Alzheimer's disease. Supporting data from the study was published in Circulation Research: Journal of the American Heart Association.

December 6, 2010 – A new stent shows favorable outcomes compared to bare metal stents (BMS) for treating coronary artery bifurcation lesions. Data for the Genous Stent, from OrbusNeich, was published online in the journal, Atherosclerosis.

December 6, 2010 – The American College of Cardiology (ACC) has partnered with Philips Healthcare on a new Hospital to Home (H2H) Learning Destination that will show how to improve the continuum of care. It will be featured at the ACC’s 60th Annual Expo in New Orleans.

December 6, 2010 – A panel of medical imaging experts discussed medical imaging appropriateness, ionizing radiation and efforts to curb overutilization, decrease radiation dose and educate patients.

December 3, 2010 – The initial patients have been enrolled in a trial for treating atrial fibrillation (AF). The DEEP AF trial will evaluate the safety and efficacy of a dual epicardial/endocardial procedure, or hybrid procedure, using AtriCure’s minimally invasive surgical ablation platform. In addition, it will use Thermocool catheter ablation products from Biosense Webster.

December 3, 2010 – The U.S. Food and Drug Administration (FDA) has given conditional approval for an Investigational Device Exception (IDE) application for a system for treating coronary artery disease. The pivotal trial will look at the Tryton Side Branch Stent.

December 3, 2010 – For the first time, data has shown that cardiac resynchronization therapy (CRT) is cost-effective in mildly symptomatic heart failure (HF) patients. Data from an economic sub-study of the REVERSE trial was published in the European Heart Journal.

November 30, 2010 – The U.S. Food and Drug Administration (FDA) has given 510(k) clearance for a suite of clinical applications that is directly integrated into PACS and cardiovascular systems. FujiFilm Medical’s Synapse 3D is vendor neutral, multi-modality capable, and can be used with virtually any advanced imaging system.

November 30, 2010 – New clinical and reporting capabilities have been added to a cardiovascular image and information system (CVIS). Version 4.0.5 of Synapse Cardiovascular, by FujiFilm Medical Systems, now features 3-D and intelligent structured reporting (ISR), enabling faster creation of consistent, high-quality echocardiography reports. Synapse 3D

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now